Pomerantz Law Firm Launches Investigation into ADMA Biologics for Potential Securities Fraud

Pomerantz Law Firm Investigates ADMA Biologics for Alleged Securities Fraud

On April 2, 2026, Pomerantz LLP announced that it is conducting an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of its investors. The firm is looking into whether ADMA, along with some of its officers and/or directors, may have engaged in securities fraud or other illicit business practices.

This investigation comes in the wake of a troubling report published by Culper Research on March 24, 2026, which accused ADMA of misleading investors regarding its revenue growth. The report suggested that the company’s reported growth figures are artificially inflated, a conclusion reached after highlighting possible practices akin to channel stuffing—where a company pushes more products through the distribution channel than can be sold to inflate sales figures. More specifically, the report claimed that without these alleged practices, ADMA’s actual revenues fell by 3% in 2025, contrary to a reported growth of 20%.

In the aftermath of the Culper Research report, ADMA’s stock price took a significant hit, dropping $2.26 per share, which amounts to a decline of approximately 16.63%. By closing on March 24, the stock had settled at $11.33 per share, a stark indication of the fallout from these revelations and the potential impact on investor sentiment.

Pomerantz LLP, a renowned legal firm with a boastful history in corporate and securities litigation, encourages affected investors to reach out to its representatives. With offices in major cities around the globe including New York, Chicago, and Tel Aviv, Pomerantz has become synonymous with class action lawsuits stemming from corporate fraud and breaches of fiduciary duty. The firm, known for its extensive experience—pioneered by the late Abraham L. Pomerantz—has been at the forefront of protecting the rights of investors against corporate malpractice for over 85 years.

Investors who have suffered losses due to their investment in ADMA Biologics are advised to contact Danielle Peyton at Pomerantz for guidance on joining the ongoing investigation and possibly participating in a class action lawsuit. The firm believes that holding companies accountable for deceptive practices is crucial for investor protection and maintaining the integrity of the market.

As revelations further unfold, investors remain vigilant in monitoring their investments in ADMA Biologics, both for potential recovery of losses and the broader implications this case may have on corporate governance in the biotech sector. Troubling reports like the one from Culper can spark significant shifts in investor confidence and stock market behavior, making it paramount for stakeholders to remain informed and ready to take action when necessary.

For those wishing to learn more or to get involved, Pomerantz provides resources on its website and can be reached via email or phone.

In an environment where transparency is increasingly demanded from corporations, the actions and policies of companies like ADMA Biologics are under intense scrutiny. It's a critical time for investors to arm themselves with knowledge and legal support as they navigate potential pitfalls and opportunities in the evolving landscape of biotechnology investments.